Isocarboxazid
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Isocarboxazid: From Depression to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Isocarboxazid is an irreversible non-selective monoamine oxidase inhibitor (MAOI) historically used to treat depression (per cited literature; it is currently not marketed in Denmark). The TxGNN model’s top-ranked prediction is Benign Paroxysmal Torticollis of Infancy, but this evidence pack contains no clinical trials and no literature supporting that specific link, and the pack’s own mechanistic assessment flags it as a likely false positive driven by graph-embedding similarity rather than pharmacology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in Danish regulatory data (drug not marketed in Denmark); literature in this pack indicates historical use for depression, incl. treatment-resistant/atypical depression (PMID 3372704) |
| Predicted New Indication | Benign Paroxysmal Torticollis of Infancy |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no structured mechanism-of-action field is available for isocarboxazid (original_moa is a data gap). However, this evidence pack’s own repurposing rationale texts describe isocarboxazid as an irreversible, non-selective MAO-A/B inhibitor that raises synaptic concentrations of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) — the classical MAOI mechanism.
For the top-ranked prediction, Benign Paroxysmal Torticollis of Infancy, the pack’s own assessment states there is no identifiable mechanistic link: this condition is thought to relate to vestibular/migraine-associated pathophysiology, which has no known connection to monoamine oxidase inhibition. The evidence pack explicitly characterizes this high TxGNN score as a likely graph-embedding artifact (false positive), and it is supported by zero clinical trials and zero publications.
By contrast, the same evidence pack contains four other distinct candidate indications for isocarboxazid — agoraphobia, obsessive-compulsive disorder, neurotic disorder, and phobic disorder — all psychiatric conditions mechanistically consistent with MAOI pharmacology. Of these, neurotic disorder and phobic disorder reach the highest evidence level in this pack (L3), supported by historical controlled/cohort studies specifically involving isocarboxazid (e.g., PMID 2404536, PMID 3372704), reflecting MAOIs’ documented historical role in atypical depression with phobic anxiety (Klein/Fink classification). These are not the subject of this report’s headline prediction but represent more pharmacologically plausible leads within the same dataset.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Isocarboxazid currently holds no marketing authorisation in Denmark (market status: Not marketed; 0 authorisations recorded in the Laegemiddelstyrelsen dataset used for this pack).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Key warnings, contraindications, and drug-interaction data are not available in this evidence pack (DDI query returned no results), and this is flagged as a blocking data gap for safety evaluation (see Conclusion).
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked TxGNN prediction (Benign Paroxysmal Torticollis of Infancy) has no supporting clinical trials, no literature, and is explicitly flagged within this evidence pack as a probable false positive with no plausible mechanistic link (Evidence Level L5, decision stage S0).
- A blocking data gap exists for Danish SmPC warnings/contraindications, which prevents any safety pre-assessment regardless of indication.
To proceed, the following is needed:
- Danish SmPC / Laegemiddelstyrelsen warning and contraindication data (currently blocking)
- Confirmed mechanism-of-action documentation for isocarboxazid
- If pursuing repurposing further, consider re-scoping the evaluation toward the pack’s higher-evidence candidates (phobic disorder and neurotic disorder, both L3 / “Research Question” stage) rather than the top raw TxGNN score
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.